Vivimed Labs Ltd Locks at Upper Circuit With 1.98% Gain — Buyers Queue, Sellers Absent

Circuit Event and Unfilled Demand

The stock, trading in the BE series, hit its upper circuit price of Rs 6.68, representing a 1.98% gain within a 2% price band. This ceiling price effectively froze trading, as the demand outstripped supply at this level. The price band of 2% allowed a modest single-day gain, but the circuit mechanism ensured that no further upward price movement was possible despite persistent buying interest. This scenario highlights the presence of unfilled demand, a common feature when stocks hit their upper circuit, especially in micro-cap segments where liquidity is limited. Vivimed Labs Ltd’s session on 25 Aug 2026 exemplifies this dynamic, with buyers willing to transact but no sellers stepping forward.

Delivery and Volume Analysis

Delivery volumes provide the clearest insight into the quality of a circuit move. On 24 Aug 2026, the delivery volume for Vivimed Labs Ltd rose by 31.94% compared to its 5-day average, reaching 36,670 shares. This increase in delivery volume suggests that the shares traded were being taken into long-term holdings rather than merely circulating intraday. However, the total traded volume on the circuit day was 0.07188 lakh shares, with a turnover of just ₹0.0048 crore, reflecting the mechanical suppression of volume due to the price lock. Volume on a circuit day is often lower than usual, but the rising delivery component signals genuine buying conviction rather than speculative frenzy — is this delivery surge a sign of sustained investor interest or a short-term momentum play?

Moving Averages and Trend Context

Vivimed Labs Ltd currently trades above its 5-day, 20-day, 50-day, and 100-day moving averages, indicating a short- to medium-term bullish trend. However, it remains below the 200-day moving average, suggesting that the longer-term trend has yet to fully confirm a sustained uptrend. The circuit event thus amplifies an already positive momentum in the near term, with the stock breaking above key shorter-term technical levels. The narrow intraday range, locked at Rs 6.68, reflects the price band constraint rather than a lack of volatility — does this technical setup support further strength once the circuit restrictions ease?

Liquidity and Market Capitalisation Context

With a market capitalisation of approximately ₹54 crore, Vivimed Labs Ltd is firmly in the micro-cap category. The liquidity profile is modest, with an effective trade size of ₹0 crore based on 2% of the 5-day average traded value, underscoring the thin order book and limited institutional participation. This liquidity constraint means that while the upper circuit signals strong buying interest, the ability to enter or exit sizeable positions is severely limited. Investors should be mindful of the liquidity risk inherent in such micro-cap stocks, where price moves can be exaggerated by relatively small volumes.

Intraday Price Action

The stock’s intraday range on the circuit day was extremely narrow, with both the high and low at Rs 6.68, reflecting the price band lock. This is typical for upper circuit hits, where the price ceiling prevents further upward movement despite ongoing demand. The absence of price fluctuation within the session indicates that the circuit mechanism was the primary factor capping the price, rather than a balance of buying and selling pressure. This locked-in price action often results in pent-up demand that may manifest once normal trading resumes.

Fundamental Snapshot

Vivimed Labs Ltd operates within the Pharmaceuticals & Drugs industry, a sector known for its cyclical and regulatory sensitivities. While the stock’s recent price action is notable, the fundamental backdrop remains a critical consideration. The micro-cap status and relatively modest turnover suggest that fundamental catalysts may be less visible in the short term, with technical and liquidity factors playing a larger role in price movements.

Conclusion: Circuit, Delivery, and Liquidity Signals

The upper circuit hit at Rs 6.68, combined with a 31.94% rise in delivery volumes the previous day and positioning above key moving averages, paints a picture of genuine buying conviction for Vivimed Labs Ltd. However, the micro-cap status and extremely limited liquidity introduce significant risk for investors attempting to transact in meaningful sizes. The circuit locked in gains but also locked out buyers who arrived late, creating unfilled demand that may influence price action once the circuit restrictions lift — after a 1.98% single-day gain at upper circuit, is Vivimed Labs Ltd still worth considering or has the move already happened?

Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today